- Baker Brothers’ 13F portfolio value increased from $14.70B to $18.81B this quarter.
- Kodiak Sciences stake was increased while decreasing Amarin Corp during the quarter.
- The top-three positions are Seattle Genetics, Incyte Corporation, and BeiGene and they add up to almost ~55% of the portfolio.
This article is part of a series that provides an ongoing
analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly
basis. It is based on Baker Brothers’ regulatory 13F Form filed on 02/14/2020.
This quarter, Baker Brothers’ 13F portfolio value increased ~28%
from $14.70B to $18.81B. The top three holdings are at ~55% while the top five
holdings are at 70% of the 13F assets: Seattle Genetics (SGEN), Incyte
Corporation (INCY), BeiGene (BGNE), Acadia Pharma (ACAD), and Alexion
Pharmaceuticals (ALXN).
The spreadsheet below highlights changes to Baker Brothers’
13F holdings in Q4 2019. For a look at how the portfolio has progressed, please
see our previous
update:
To learn more about how to profit from a strategy of
following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little
Guy .
No comments :
Post a Comment